Cancer reports最新文献

{"title":"Association Aamong Ppolymorphisms in the Aapoptosis-Rrelated NKX3-1, Caspase-3, Caspase-9, and BCL-2 Genes and Prostate Cancer Susceptibility From 9706 Cases and 12,567 Controls","authors":"Yanyan Feng,&nbsp;Zhenting Feng,&nbsp;Dan Li,&nbsp;Jiandong Gui,&nbsp;Zhihong Song,&nbsp;Xiaohua Xie,&nbsp;Lijie Zhu,&nbsp;Yuanyuan Mi","doi":"10.1002/cnr2.70206","DOIUrl":"https://doi.org/10.1002/cnr2.70206","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While there is a growing volume of evidence suggesting that relatively prevalent functional polymorphisms present within apoptosis-related genes may influence human prostate cancer (PCa) susceptibility, the clinical relevance of these findings remains inconclusive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This meta-analysis was thus developed with the goal of generating more precise estimates of the relationships between polymorphisms in four apoptosis-associated genes (NKX3-1, caspase-3, caspase-9, and BCL-2) and the risk of PCa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The PubMed, Web of Science, Google Scholar, Embase, Cochrane Library, and SinoMed (CNKI and Wanfang) databases were searched for relevant studies published through December 20, 2023, using the following keywords: “polymorphism” or “variant” and “carcinoma” or “cancer” or “tumor” and “NKX3-1,” “CASP3” or “Caspase-3,” “CASP9” or “Caspase-9,” “BCL-2” or “B-cell lymphoma” and “prostate cancer” or “PCa” or “prostate adenocarcinoma.” This approach led to the identification of 22 case–control studies related to the association between apoptosis-related gene polymorphisms and PCa susceptibility enrolling 9706 cases and 12 567 controls. Subsequent analyses revealed that the <i>NKX3-1</i> rs2228013, <i>CASP9</i> rs1052571, and <i>CASP9</i> rs4645982 polymorphisms were associated with greater PCa risk, whereas the <i>CASP3</i> rs4647603 polymorphism was associated with a risk reduction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings provide strong evidence for the potential contributions of polymorphisms in the apoptosis-related caspase-3, caspase-9, and NKX3-1 genes in the onset and progression of PCa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma","authors":"Yifei Chen,&nbsp;Jun Liu,&nbsp;Ying Zhu","doi":"10.1002/cnr2.70216","DOIUrl":"https://doi.org/10.1002/cnr2.70216","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple myeloma is a malignant disorder involving the uncontrolled proliferation of plasma cells in the bone marrow. Prognosis remains poor for individuals with relapsed and refractory multiple myeloma (RRMM), and the underlying mechanisms are yet to be fully understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected bone marrow RNA-Seq data from a total of 557 patients with MM from the GEO database (GSE24080) for further analysis, dividing them into relapsed/refractory and control groups. Additionally, we collected bone marrow samples from 57 MM patients to validate the performed RNA-Seq data analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RNA-Seq analysis of patients with RRMM revealed a significant upregulation of genes associated with cuproptosis. Using the LASSO Cox regression method, several long noncoding RNAs (lncRNAs) were identified that influence copper-induced cell death. Based on these lncRNAs, patients were stratified into high-risk and low-risk groups. The high-risk group exhibited a significantly worse overall survival (OS) compared to the low-risk group, with a <i>p</i>-value of less than 0.001. Our statistical analysis, incorporating LASSO Cox regression, indicated that among these lncRNAs, MAMDC2-AS1 was particularly noteworthy due to its strong correlation with OS (<i>p</i>-value &lt; 0.01). Further validation using qPCR and survival analysis established MAMDC2-AS1 as a strong predictor of prognosis in MM. This finding suggests that MAMDC2-AS1 can serve as a potential independent biomarker for RRMM. The qPCR data validated the RNA-Seq findings and uncovered the significance of MAMDC2-AS1 in the prognosis of this disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MAMDC2-AS1 plays a significant role in RRMM. Promisingly, Bortezomib, Bosutinib, Crizotinib, and DMOG have demonstrated promising efficacy in addressing advanced cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Nomogram for Lung Adenocarcinoma Patients With Bone Metastasis Based on the SEER Database and an External Validation Cohort","authors":"Zhiming Liu,&nbsp;Min Zhang,&nbsp;Shuo Han,&nbsp;Hao Zhang,&nbsp;Shengwei Meng,&nbsp;Zhubin Shen,&nbsp;Xuexiao Ma","doi":"10.1002/cnr2.70211","DOIUrl":"https://doi.org/10.1002/cnr2.70211","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung adenocarcinoma is a common type of cancer that can lead to bone metastasis and has a poor prognosis. Although previous studies have established nomograms for lung adenocarcinoma, these nomograms do not effectively predict the prognosis of lung adenocarcinoma patients with bone metastasis. This study aims to establish and validate a new nomogram to solve this problem.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were collected from the SEER database and from patients at our hospital who had been diagnosed with lung adenocarcinoma and developed bone metastases. The patients were randomly assigned into the training and internal validation sets in a 7:3 ratio. External validation was conducted using an independent patient cohort from two hospitals. Different methods were used to evaluate the nomogram's performance. The relationship between different metastatic sites and radiotherapy and chemotherapy was also analyzed to evaluate patient prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The following factors were identified as significant prognostic indicators: age, sex, marital status, T stage, N stage, tumor grade, tumor size, presence of brain and liver metastases, and receipt of chemotherapy. The nomogram's concordance indices for predicting overall survival were consistently above 0.7, and the area under the curve values, calibration plots, and decision curves all confirmed the nomogram's strong predictive accuracy. Moreover, our analysis revealed that chemotherapy was the most effective treatment modality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study developed a nomogram that can predict the prognosis of lung adenocarcinoma patients with bone metastasis. The results showed that patients with liver metastasis had the worst prognosis and that chemotherapy was the most effective treatment regimen for patients with different metastatic sites.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor-Induced Hypertension in Patients With Renal Cell Carcinoma","authors":"Satoru Nakanishi,&nbsp;Keisuke Ikegami,&nbsp;Shungo Imai,&nbsp;Hayato Kizaki,&nbsp;Satoko Hori","doi":"10.1002/cnr2.70219","DOIUrl":"https://doi.org/10.1002/cnr2.70219","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although hypertension is a common side effect of tyrosine kinase inhibitor (TKI) treatment for renal cell carcinoma (RCC), there is limited evidence regarding its occurrence and related risk factors. Preliminary studies suggest that proton pump inhibitors (PPIs) may mitigate the risk of TKI-induced hypertension; however, their clinical effectiveness remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this study, we examined the prevalence of TKI-induced hypertension and the patterns of antihypertensive prescriptions among patients with RCC in Japan. Additionally, we investigated factors associated with TKI-induced hypertension to assess the potential impact of PPIs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Data from patients diagnosed with RCC who were prescribed TKIs between April 2008 and July 2021 were retrospectively gathered from a Japanese administrative database. TKI-induced hypertension was detected following the diagnosis of hypertension and subsequently the prescription of an antihypertensive agent during TKI therapy. The prescription details for antihypertensive agents were organized in a tabular format. Cox proportional hazards regression analysis was conducted to examine factors contributing to TKI-induced hypertension. Among the 225 patients analyzed, 36.4% experienced hypertension, and calcium channel blockers were the most prescribed antihypertensive agents. Pre-existing hypertension was identified as a risk factor for TKI-induced hypertension, while the concurrent use of PPIs did not show a tendency to reduce the risk of TKI-induced hypertension.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings indicate the importance of blood pressure management in patients with elevated baseline blood pressure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delay Patterns and Associated Factors Among Gastric Cancer Patients Visiting Tertiary Hospital in Ethiopia","authors":"Tsegab Alemayehu,&nbsp;Semira Abdelmenan,&nbsp;Hailu Wondimu,&nbsp;Segni Kejela,&nbsp;Firaol Dandena,&nbsp;Tesfahun Ali,&nbsp;Zewdu Abadi,&nbsp;Zekarias Seifu","doi":"10.1002/cnr2.70209","DOIUrl":"https://doi.org/10.1002/cnr2.70209","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer ranks sixth in terms of incidence and fifth in terms of mortality in the world. It is also the fifth most frequent cancer in Ethiopia. In developed countries such as Japan, the diagnosis of gastric cancer is made early and has a better prognosis, but in developing countries like Ethiopia, the majority of patients present late in the advanced state. This study assessed delay patterns and associated factors among gastric cancer patients in Tikur Anbessa Specialized Hospital in Ethiopia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-center cross-sectional study was conducted on 64 gastric cancer patients on follow-up from February 2021 to March 2023. The main outcome measures are the mean length of total delay, patient delay, diagnosis delay, and treatment delay. SPSS software version 26 and the Mann–Whitney statistical test were used to verify associations between the time intervals of access to treatment and socioeconomic factors, clinical variables, and patient-reported reasons, adopting a 0.05 significance level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, the mean length of patient delay was 106 (SD = 142) days, the diagnosis delay was 318 (SD = 370) days, and the treatment delay was 43 (SD = 43) days. The average length of the total delay between symptom onset and definitive treatment was 467.4 (SD = 396.3) days. The greater length of patient delay in this study was correlated with lack of awareness (<i>p</i> &lt; 0.001), search for traditional alternatives (<i>p</i> value 0.02), rural residence (<i>p</i> = 0.05), and economic hindrances (<i>p</i> = 0.01), and diagnosis delay was correlated with misdiagnosis (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion and Recommendation</h3>\u0000 \u0000 <p>Delays among gastric cancer patients in this study are much greater than those seen in other low-income countries. Patient delay and diagnosis delay have a lion's share in the breakdown of the delays in our setup. Lack of awareness, the search for traditional alternatives, economic hindrances, and misdiagnosis were associated factors for delays. We recommend training primary healthcare providers regarding early signs of gastric cancer and integrating community-based public health interventions to increase awareness of cancer and early health-seeking behaviors. Along with increasing oncologic centers both by numbers and by quality of services.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis","authors":"Takahiro Koyanagi,&nbsp;Yasushi Saga,&nbsp;Yoshifumi Takahashi,&nbsp;Kohei Tamura,&nbsp;Eri Suizu,&nbsp;Suzuyo Takahashi,&nbsp;Akiyo Taneichi,&nbsp;Yuji Takei,&nbsp;Hiroaki Mizukami,&nbsp;Hiroyuki Fujiwara","doi":"10.1002/cnr2.70202","DOIUrl":"https://doi.org/10.1002/cnr2.70202","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Progesterone rapidly induces ovarian cancer cell death through non-genomic actions mediated by the membrane progesterone receptor (mPR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We investigated the combined effects of progesterone and SN38, an active metabolite of irinotecan, on ovarian cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>mPR-positive and PR-negative ovarian cancer cell lines were utilized in experiments. Tumor cells were exposed to SN38 or cisplatin for 48 h following exposure to progesterone for 30 min. The viable cell counts were measured using a colorimetric assay and the expression of topoisomerase I (TOPO-I), the direct target of SN38, was observed with or without exposure to progesterone. Moreover, we investigated the relationship between several types of programmed cell death and the SN38 sensitivity enhancement effect of progesterone using specific cell death inhibitors. The chemosensitivity to SN38 was 8.7- to 26.0-fold higher with the administration of progesterone than that without (<i>p</i> &lt; 0.01), but not to cisplatin in ovarian cancer cells. Progesterone suppressed the expression of TOPO-I mRNA by less than 50% (<i>p</i> &lt; 0.01). Furthermore, among various programmed cell death inhibitors, only the ferroptosis inhibitor attenuated the progesterone-induced SN38 chemosensitivity enhancement effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Progesterone increased sensitivity to SN38 by suppressing TOPO-I expression and inducing ferroptosis. The combination of progesterone and irinotecan could be a novel treatment modality for ovarian cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Surgical Treatment for Metastatic Bone Disease of the Forearm","authors":"Jennifer Sebghati,&nbsp;Panagiotis Tsagkozis","doi":"10.1002/cnr2.70208","DOIUrl":"https://doi.org/10.1002/cnr2.70208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metastatic bone disease and pathological fractures in the long bones of the forearm are rare. The methods and outcomes of surgical treatment for these fractures have not been adequately described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To analyze the outcome of surgery for pathological fractures of the forearm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Retrospective study of 30 complete and impending pathological fractures (28 consecutive patients) in the forearm, operated on in a single tertiary center between 1986 and 2020. The most common malignancy was hematological disease (multiple myeloma and lymphoma). Most fractures (<i>n</i> = 19) were managed with plate and screw reconstruction. In some cases, simple curettage or segmental resections of the metastasis were performed. Local complications were noted in six operations, the most common one being tumor relapse seen in three patients. Most patients had good outcomes regarding restoration of function and pain relief. There were no secondary surgeries in segmental resection, and the function was near normal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Surgical reconstruction of metastases in the long bones of the forearm usually results in a good functional outcome with an acceptable complication rate. Plate osteosynthesis is often indicated. Segmental excision can be reserved for dispensable parts of the ulna and radius, with excellent results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70208","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cost-Effectiveness of a Multi-Target Stool DNA-Based Screening (COLOTECT), FIT, Colonoscopy and No Screening for Colorectal Cancer","authors":"Junjie Huang,&nbsp;Mingtao Chen,&nbsp;Victor C. W. Chan,&nbsp;Xianjing Liu,&nbsp;Chaoying Zhong,&nbsp;Jianli Lin,&nbsp;Junjie Hang,&nbsp;Claire Chenwen Zhong,&nbsp;Jinqiu Yuan,&nbsp;Martin C. S. Wong","doi":"10.1002/cnr2.70176","DOIUrl":"https://doi.org/10.1002/cnr2.70176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Around 1.9 million new cases and 1 million deaths worldwide were attributed to colorectal cancer (CRC) in 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aims of this study are to assess the cost-effectiveness of a multi-target stool DNA-based screening strategy, COLOTECT, compared to faecal immunochemical tests (FIT), colonoscopy, and no screening in the Asian population to inform more choices for policymakers in colorectal cancer screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method and Results</h3>\u0000 \u0000 <p>We assume that 100,000 persons aged 50 undergo annual FIT, annual COLOTECT multi-target testing, or colonoscopies every 10 years until age 75. The data used in this study was retrieved from different sources including the Hong Kong Cancer Registry and previously published studies on the population aged 50 to 75 years old between 2010 and 2023. This study accessed the most cost-effective screening strategy available. If a positive result of FIT or COLOTECT were observed, the participants would undergo a colonoscopy. The participants who used the colonoscopy as the main screening method conducted colonoscopies every 3 years. The Markov models were utilized to compare the outcomes from different strategies including life-years saved, years of life lost, and incremental cost-effectiveness ratio (primary outcome). The highest ICER was observed in colonoscopy (USD 160808), followed by FIT (USD 108952), and COLOTECT (USD 82206). A higher detection rate of CRC (COLOTECT: 39.3% vs. FIT: 4.5%), more CRC cases prevented (1272 vs. 146), and life-years saved (2295 vs. 337) were observed in the COLOTECT strategy than in FIT. Additionally, a lower total cost per life-year saved of COLOTECT (USD 180097) was observed than colonoscopy (USD 238356), which identified the more affordable and cost-saving COLOTECT strategy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlighted the better performance of COLOTECT than FIT in detecting CRC. Additionally, given its lower cost and higher acceptance, the COLOTECT strategy might be more cost-effective than colonoscopy for massive CRC screening.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Cancer Metastasis: From Mechanisms to Treatments and Beyond","authors":"Mukul S. Godbole,&nbsp;Amruta Naik","doi":"10.1002/cnr2.70201","DOIUrl":"https://doi.org/10.1002/cnr2.70201","url":null,"abstract":"&lt;p&gt;Metastasis is an important attribute of cancer cells. If and when the primary tumor microenvironment becomes less conducive for growth and sustenance, metastatic growth allows cancer cells to explore potentially more conducive environments for survival and territorial expansion, instead of perishing at the original site. Cancer cells utilize multiple cellular mechanisms for processes such as detaching from the initial tumor site (migration and invasion), intravasation (crossing the endothelial barrier), circulation (movement through blood and/or lymph), extravasation (exit from circulation into a secondary tissue), and colonization (establishment of micro-metastases). These processes are further supported by angiogenesis (development of new blood vessels), immune evasion (overcoming immune regulation), modulation of primary and secondary tissue microenvironments (modulation of tumor-infiltrating immune cell activity, suppression of antitumor effects, etc.), secretion of tissue growth factors supporting metastases, and evasion of cell death. Moreover, the smooth transitions and interlinks between each of these processes adds to the complexity of metastasis and, hence, makes it difficult and crucial to target the processes that allow systemic spread of cancer cells. The “Cancer Metastasis: Mechanisms and Treatment” special issue primarily focuses on discussing the various mechanisms that drive metastasis of cancer cells to regional or distant organs and explores the strategies to target these metastatic processes, ultimately aiming to improve patient outcomes. We believe that the research and review articles published as part of the special issue would collectively aid in improving our current understanding and allow more critical research in the field. Here, we provide glimpses of all articles published in the special issue and encourage the readers to further dwell into the intricacies discussed in each of the articles.&lt;/p&gt;&lt;p&gt;Breast cancer, known for its high prevalence and tumor heterogeneity among women, frequently metastasizes to distant organs, such as the brain, lungs, liver, lymph nodes, and bones, leading to poor survival outcomes. Unfortunately, traditional treatments such as chemotherapy, radiotherapy, endocrine therapy, and immunotherapy show limited success in patients with metastatic breast cancer. A review article by Naik and Godbole offers a comprehensive discussion on the interesting, yet underexplored, roles of gut and breast microbiomes in influencing breast cancer metastasis, particularly to the bone [&lt;span&gt;1&lt;/span&gt;]. The article elaborates on the mechanisms by which microorganisms either promote or abrogate breast cancer metastasis, such as epithelial–mesenchymal transition, immune modulation in the bone microenvironment, enhanced cancer cell survival in circulation due to bacteria-induced altered cytoskeletal architecture, intratumoral persistence of bacteria in metastasizing cancer cells, altered steroid hormone metabolism","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S-1 + Oxaliplatin Chemotherapy for Gastric Cancer","authors":"Naoki Urakawa,&nbsp;Shingo Kanaji,&nbsp;Ryuichiro Sawada,&nbsp;Yasufumi Koterazawa,&nbsp;Taro Ikeda,&nbsp;Hitoshi Harada,&nbsp;Hironobu Goto,&nbsp;Hiroshi Hasegawa,&nbsp;Kimihiro Yamashita,&nbsp;Takeru Matsuda,&nbsp;Yoshihiro Kakeji","doi":"10.1002/cnr2.70190","DOIUrl":"https://doi.org/10.1002/cnr2.70190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoadjuvant chemotherapy is widely recognized as the established treatment for advanced gastric cancer. However, predicting its efficacy before surgery remains challenging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study aimed to evaluate the effectiveness of 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) as a predictor of treatment response to the S-1+Oxaliplatin regimen (SOX).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Thirty patients who underwent gastrectomy following neoadjuvant SOX between January 2021 and July 2023 were included. Patients underwent FDG-PET pre- and postsurgery. The maximum standardized uptake value (SUVmax) from FDG-PET was examined in relation to histological tumor response and prognosis. SUVmax decreased significantly after chemotherapy in all patients (<i>p</i> &lt; 0.001), especially in those with Grade 1a, 2, and 3 tumors (<i>p &lt;</i> 0.05). SUV reduction increased stepwise with the histological response grade. Optimal cut-off values for the percentage decrease in SUVmax (ΔSUVmax) predictive of histologic efficacy were identified as 53% (area under curve 0.855, <i>p =</i> 0.0018) for Grade 1b or higher and 75% (area under curve 0.806, <i>p</i> = 0.0044) for Grade 2 or higher. Patients with ΔSUVmax &gt; 50% had improved recurrence-free survival (<i>p =</i> 0.027).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>FDG-PET may be useful as a predictor of treatment response in neoadjuvant SOX therapy for gastric cancer. The determination of the optimal ΔSUVmax value may enhance the precision of histological tumor response prediction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}